NO20072571L - Fremgangsmater for gjenfolding av rekombinante antistoffer - Google Patents
Fremgangsmater for gjenfolding av rekombinante antistofferInfo
- Publication number
- NO20072571L NO20072571L NO20072571A NO20072571A NO20072571L NO 20072571 L NO20072571 L NO 20072571L NO 20072571 A NO20072571 A NO 20072571A NO 20072571 A NO20072571 A NO 20072571A NO 20072571 L NO20072571 L NO 20072571L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- recombinant antibodies
- refolding recombinant
- refolding
- igg proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
- A61K39/39525—Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62129504P | 2004-10-22 | 2004-10-22 | |
US70176205P | 2005-07-22 | 2005-07-22 | |
PCT/US2005/038045 WO2006047340A2 (en) | 2004-10-22 | 2005-10-21 | Methods for refolding of recombinant antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20072571L true NO20072571L (no) | 2007-07-20 |
Family
ID=36129791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20072571A NO20072571L (no) | 2004-10-22 | 2007-05-21 | Fremgangsmater for gjenfolding av rekombinante antistoffer |
Country Status (16)
Country | Link |
---|---|
US (1) | US7928205B2 (ru) |
EP (1) | EP1805320B1 (ru) |
JP (2) | JP5553963B2 (ru) |
KR (1) | KR101370253B1 (ru) |
AU (1) | AU2005299716B2 (ru) |
BR (1) | BRPI0517457A (ru) |
CA (1) | CA2584211C (ru) |
EA (1) | EA012162B1 (ru) |
IL (1) | IL182626A0 (ru) |
MA (1) | MA29027B1 (ru) |
MX (1) | MX2007004437A (ru) |
NO (1) | NO20072571L (ru) |
NZ (1) | NZ554520A (ru) |
RU (1) | RU2007118954A (ru) |
SG (1) | SG156672A1 (ru) |
WO (1) | WO2006047340A2 (ru) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG156672A1 (en) * | 2004-10-22 | 2009-11-26 | Amgen Inc | Methods for refolding of recombinant antibodies |
AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US7476852B2 (en) * | 2005-05-17 | 2009-01-13 | Honeywell International Inc. | Ionization-based detection |
MX2007014148A (es) * | 2005-05-19 | 2008-01-11 | Amgen Inc | Composiciones y metodos para incrementar la estabilidad de anticuerpos. |
EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
EP4001409A1 (en) * | 2006-03-31 | 2022-05-25 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
PE20081179A1 (es) * | 2006-10-06 | 2008-09-29 | Amgen Inc | Formulaciones estables de anticuerpos egfr |
US7705132B2 (en) * | 2006-10-20 | 2010-04-27 | Amgen Inc. | Stable polypeptide formulations |
AU2007338013A1 (en) * | 2006-12-22 | 2008-07-03 | Ares Trading S.A. | Analytical method for analyzing C-terminus truncation |
EP2626372B1 (en) | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispecific antibodies and methods for production thereof |
CN101932591B (zh) | 2007-07-09 | 2018-02-16 | 健泰科生物技术公司 | 在多肽的重组生产期间防止二硫键还原 |
WO2009036209A2 (en) * | 2007-09-14 | 2009-03-19 | Amgen Inc. | Homogeneous antibody populations |
WO2009041621A1 (ja) | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | 抗il-6レセプター抗体 |
AU2016202036B2 (en) * | 2007-09-26 | 2017-12-07 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
PE20090711A1 (es) * | 2007-09-26 | 2009-07-15 | Chugai Pharmaceutical Co Ltd | Region constante de anticuerpo mutante |
JP5682995B2 (ja) * | 2007-12-05 | 2015-03-11 | 中外製薬株式会社 | 抗nr10抗体、およびその利用 |
CA2718289A1 (en) * | 2008-03-12 | 2009-09-17 | Imclone Llc | Anti-tyrp1 antibodies |
KR102084925B1 (ko) | 2008-04-11 | 2020-03-05 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
JP5646457B2 (ja) * | 2008-04-29 | 2014-12-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
EP3002299A1 (en) * | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
KR20110016959A (ko) * | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
AU2009268585C1 (en) * | 2008-07-08 | 2014-10-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
BRPI0917298B8 (pt) * | 2008-08-19 | 2021-05-25 | Glytech Inc | método de produção de glicoproteína e método de rastreamento de glicoproteína |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
JP5787446B2 (ja) * | 2009-03-19 | 2015-09-30 | 中外製薬株式会社 | 抗体定常領域改変体 |
JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
CA2759370C (en) | 2009-04-30 | 2020-02-11 | Peter Schotte | Method for the production of domain antibodies |
KR20140014382A (ko) * | 2009-05-01 | 2014-02-06 | 애브비 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
JP5669732B2 (ja) | 2009-05-15 | 2015-02-12 | 中外製薬株式会社 | 抗axl抗体 |
BRPI1011940B8 (pt) | 2009-06-22 | 2021-08-03 | Amgen Inc | método de redobramento de uma proteína expressa em um sistema de expressão de não mamífero |
EP3660032A1 (en) | 2009-06-25 | 2020-06-03 | Amgen, Inc | Capture purification processes for proteins expressed in a non-mammalian system |
UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
WO2011037158A1 (ja) | 2009-09-24 | 2011-03-31 | 中外製薬株式会社 | 抗体定常領域改変体 |
EP2483289B1 (en) | 2009-10-02 | 2019-03-20 | Biogen MA Inc. | Methods of preventing and removing trisulfide bonds |
BR112012008833A2 (pt) * | 2009-10-15 | 2015-09-08 | Abbott Lab | imunoglobulinas de dominio variavel duplo e usos das mesmas |
UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
AU2011244282A1 (en) | 2010-04-20 | 2012-11-15 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
MY160445A (en) | 2010-08-03 | 2017-03-15 | Abbvie Inc | Dual Variable Domain Immunoglobulins And Uses Thereof |
RU2013113225A (ru) | 2010-08-26 | 2014-10-10 | Эббви Инк. | Иммуноглобулины с двумя вариабельными доменами и их применение |
CN108715614A (zh) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
PL2702164T3 (pl) | 2011-04-29 | 2016-06-30 | Biocon Res Limited | Sposób obniżania heterogeniczności przeciwciał i sposób ich wytwarzania |
WO2012158551A1 (en) | 2011-05-13 | 2012-11-22 | Biogen Idec Ma Inc. | Methods of preventing and removing trisulfide bonds |
DK2771364T3 (da) * | 2011-10-27 | 2019-08-19 | Genmab As | Fremstilling af heterodimere proteiner |
CA2857194A1 (en) * | 2011-12-07 | 2013-06-13 | Thomas M. Dillon | Igg2 disulfide isoform separation |
JP2015508994A (ja) | 2011-12-30 | 2015-03-26 | アッヴィ・インコーポレイテッド | Il−13および/またはil−17に対する二重可変ドメイン免疫グロブリン |
CN104507955A (zh) * | 2012-05-31 | 2015-04-08 | 新加坡科技研究局 | 采用具有多形式官能性的颗粒对免疫球蛋白g制备物的色谱纯化 |
KR20190096459A (ko) | 2012-11-01 | 2019-08-19 | 애브비 인코포레이티드 | 항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도 |
CA2902854C (en) | 2013-03-08 | 2024-01-23 | Genzyme Corporation | Integrated continuous manufacturing of therapeutic protein drug substances |
MX2015013166A (es) | 2013-03-15 | 2015-12-11 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17. |
KR20150134372A (ko) * | 2013-03-29 | 2015-12-01 | 다이소 가부시키가이샤 | 세포 배양용 배지 첨가물 |
EP3030249B1 (en) * | 2013-08-07 | 2019-12-25 | Rigshospitalet, Copenhagen University Hospital | Antibodies, compounds and derivatives thereof for use in the treatment of male infertility |
CA2921999C (en) | 2013-09-13 | 2023-03-21 | Genentech, Inc. | Methods and compositions comprising an anti-il13 antibody and residual hamster phospholipase b-like 2 |
EP3044323B1 (en) * | 2013-09-13 | 2022-04-06 | F. Hoffmann-La Roche AG | Methods for detecting and quantifying host cell protein in cell lines |
WO2015046467A1 (ja) | 2013-09-27 | 2015-04-02 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
TWI709569B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析樹脂及其用於製造方法的用途 |
TWI709570B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析法及製法 |
KR102376287B1 (ko) | 2014-04-02 | 2022-03-17 | 에프. 호프만-라 로슈 아게 | 다중특이적 항체 경쇄 잘못짝짓기의 검출 방법 |
US10647777B2 (en) | 2014-05-28 | 2020-05-12 | Genzyme Corporation | Methods of controlling the formation of disulfide bonds in protein solutions |
RS60631B1 (sr) | 2014-11-21 | 2020-09-30 | Bristol Myers Squibb Co | Antitela protiv cd73 i njihova upotreba |
PL3221346T3 (pl) | 2014-11-21 | 2021-03-08 | Bristol-Myers Squibb Company | Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego |
WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
DK3233907T3 (da) | 2014-12-19 | 2021-06-07 | Genmab As | Bispecifikke heterodimeriske proteiner hos gnavere |
MX2017007670A (es) * | 2014-12-22 | 2017-10-27 | Ucb Biopharma Sprl | Metodo de manufactura de proteina. |
AR103172A1 (es) | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
WO2016136933A1 (ja) | 2015-02-27 | 2016-09-01 | 中外製薬株式会社 | Il-6関連疾患治療用組成物 |
WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
US11312745B2 (en) * | 2016-07-22 | 2022-04-26 | Amgen Inc. | Methods of purifying Fc-containing proteins |
WO2018018613A1 (zh) | 2016-07-29 | 2018-02-01 | 广东东阳光药业有限公司 | 一种提高抗体纯度的细胞培养基和培养方法 |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
EP3672632A1 (en) * | 2017-08-22 | 2020-07-01 | Biogen MA Inc. | Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies |
TW201923069A (zh) | 2017-10-02 | 2019-06-16 | 美商拜耳保健有限責任公司 | 以亞硒酸鹽防止細胞培養收獲物中雙硫鍵還原之方法 |
CN111246885B (zh) | 2017-10-20 | 2024-06-11 | 豪夫迈·罗氏有限公司 | 从单特异性抗体生成多特异性抗体的方法 |
CN111372947A (zh) | 2017-10-30 | 2020-07-03 | 豪夫迈·罗氏有限公司 | 在体内从单特异性抗体产生多特异性抗体的方法 |
US11952422B2 (en) | 2017-12-05 | 2024-04-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137 |
US11447547B1 (en) | 2017-12-13 | 2022-09-20 | Amgen Inc. | Method of antigen-binding protein production |
US11891432B2 (en) | 2018-03-15 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use |
EA202092335A1 (ru) | 2018-04-02 | 2021-01-22 | Эмджен Инк. | Композиции на основе эренумаба и пути их применения |
KR20210045425A (ko) * | 2018-08-15 | 2021-04-26 | 브리스톨-마이어스 스큅 컴퍼니 | 하류 크로마토그래피에서의 재산화에 의한 단백질 단편화 제어 전략 |
SG11202101860UA (en) | 2018-08-31 | 2021-03-30 | Genzyme Corp | Sterile chromatography resin and use thereof in manufacturing processes |
US10899826B1 (en) | 2018-09-13 | 2021-01-26 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for an anti-CGRP antagonist antibody |
AR117650A1 (es) * | 2018-10-11 | 2021-08-18 | Amgen Inc | Procesamiento posterior de constructos de anticuerpos biespecíficos |
EP4126970A4 (en) | 2020-03-31 | 2024-05-01 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PRODUCING MULTI-SPECIFIC ANTIGEN-BINDING MOLECULES |
EP4126969A4 (en) | 2020-03-31 | 2024-05-29 | Chugai Seiyaku Kabushiki Kaisha | MULTISPECIFIC ANTIGEN-BINDING MOLECULES TARGETING DLL3 AND THEIR USES |
CA3192069A1 (en) * | 2020-09-14 | 2022-03-17 | Michael Spector | Method of treating amyloidosis |
KR20240055101A (ko) * | 2021-09-14 | 2024-04-26 | 시일럼 바이오사이언시즈, 인크. | 다발성 골수종의 치료 방법 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4870009A (en) * | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4745051A (en) * | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
US4952496A (en) * | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4766205A (en) * | 1985-11-13 | 1988-08-23 | Beatrice Companies, Inc. | Method for isolation of recombinant polypeptides in biologically active forms |
US4737323A (en) * | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
EP0293785A3 (en) | 1987-05-29 | 1990-05-02 | Oncogen Limited Partnership | Cloning and expression of simian transforming growth factor-ss1 |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5242687A (en) * | 1989-03-15 | 1993-09-07 | Tkb Associates Limited Partnership | Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells |
US5272071A (en) * | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
US5169784A (en) * | 1990-09-17 | 1992-12-08 | The Texas A & M University System | Baculovirus dual promoter expression vector |
US5266317A (en) * | 1990-10-04 | 1993-11-30 | University Of Georgia Research Foundation, Inc. | Insect-specific paralytic neurotoxin genes for use in biological insect control: methods and compositions |
DE4113750A1 (de) | 1991-04-26 | 1992-10-29 | Boehringer Mannheim Gmbh | Verbesserung der renaturierung bei der sekretion von disulfidverbrueckten proteinen |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
US5243041A (en) * | 1991-08-22 | 1993-09-07 | Fernandez Pol Jose A | DNA vector with isolated CDNA gene encoding metallopanstimulin |
WO1993008207A1 (en) | 1991-10-25 | 1993-04-29 | Immunex Corporation | Novel cytokine |
AU648214B2 (en) | 1991-12-31 | 1994-04-14 | Lucky Limited | Recombinant gene coding for human alpha interferon and expression vector thereof, etc. |
AU6492194A (en) * | 1993-04-01 | 1994-10-24 | Schering Corporation | (in vitro) refolding of recombinant fv fragments |
WO1995032216A1 (en) | 1994-05-25 | 1995-11-30 | University Of Nebraska Board Of Regents | Biologically active glycoprotein hormones produced in procaryotic cells |
EP0766564A4 (en) * | 1994-06-24 | 1998-09-23 | Immunex Corp | SLOW RELEASE POLYPEPTIDES COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL CONDITIONS |
HUT76666A (en) | 1994-07-22 | 1997-10-28 | Hoffmann La Roche | Pharmaceutical compositions comprising a chimaeric tnf binding protein |
DK0832229T3 (da) | 1995-06-07 | 2004-05-03 | Immunex Corp | CD40L-mutein |
US6063905A (en) * | 1997-01-07 | 2000-05-16 | Board Of Regents, The University Of Texas System | Recombinant human IGA-J. chain dimer |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
FR2803303B1 (fr) | 2000-01-04 | 2002-05-10 | Aventis Pasteur | Glycoproteine d'enveloppe du vih modifiee chimiquement |
AUPQ599700A0 (en) * | 2000-03-03 | 2000-03-23 | Super Internet Site System Pty Ltd | On-line geographical directory |
CA2433353C (en) | 2000-12-28 | 2017-03-21 | Altus Biologics, Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
CZ20032208A3 (cs) * | 2001-02-23 | 2004-01-14 | Immunex Corporation | Zvýšený výtěžek aktivních proteinů |
AU2002322295C1 (en) | 2001-06-21 | 2008-12-18 | Altus Pharmaceuticals Inc. | Spherical protein particles and methods of making and using them |
DK1425389T3 (da) * | 2001-08-23 | 2012-01-30 | Genmab As | Interleukin-15-(IL-15)-specifikke humane antistoffer |
US7247304B2 (en) * | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
ATE518886T1 (de) * | 2003-06-09 | 2011-08-15 | Redox Reactive Reagents L L C | Verfahren zur änderung der bindungsspezifität von plasmaproteinen durch oxidations- reduktionsreaktionen |
US9557325B2 (en) * | 2003-06-09 | 2017-01-31 | Redox-Reactive Reagents Llc | Method of altering the binding specificity of proteins by oxidation-reduction reactions |
US7329353B2 (en) | 2004-01-23 | 2008-02-12 | Amgen Inc. | LC/MS method of analyzing high molecular weight proteins |
SG156672A1 (en) * | 2004-10-22 | 2009-11-26 | Amgen Inc | Methods for refolding of recombinant antibodies |
US7825223B2 (en) * | 2005-06-17 | 2010-11-02 | Janssen Alzheimer Immunotherapy | Methods of purifying anti A β antibodies |
-
2005
- 2005-10-21 SG SG200907043-4A patent/SG156672A1/en unknown
- 2005-10-21 KR KR1020077011651A patent/KR101370253B1/ko active IP Right Grant
- 2005-10-21 EA EA200700917A patent/EA012162B1/ru not_active IP Right Cessation
- 2005-10-21 WO PCT/US2005/038045 patent/WO2006047340A2/en active Application Filing
- 2005-10-21 RU RU2007118954/13A patent/RU2007118954A/ru not_active Application Discontinuation
- 2005-10-21 EP EP05811874.6A patent/EP1805320B1/en not_active Revoked
- 2005-10-21 JP JP2007538098A patent/JP5553963B2/ja active Active
- 2005-10-21 US US11/255,528 patent/US7928205B2/en active Active
- 2005-10-21 AU AU2005299716A patent/AU2005299716B2/en active Active
- 2005-10-21 MX MX2007004437A patent/MX2007004437A/es active IP Right Grant
- 2005-10-21 NZ NZ554520A patent/NZ554520A/en not_active IP Right Cessation
- 2005-10-21 CA CA2584211A patent/CA2584211C/en active Active
- 2005-10-21 BR BRPI0517457-0A patent/BRPI0517457A/pt not_active IP Right Cessation
-
2007
- 2007-04-17 IL IL182626A patent/IL182626A0/en unknown
- 2007-05-17 MA MA29914A patent/MA29027B1/fr unknown
- 2007-05-21 NO NO20072571A patent/NO20072571L/no not_active Application Discontinuation
-
2012
- 2012-12-25 JP JP2012281266A patent/JP2013055961A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2006047340A3 (en) | 2007-07-05 |
MX2007004437A (es) | 2007-06-20 |
EA012162B1 (ru) | 2009-08-28 |
AU2005299716B2 (en) | 2012-09-06 |
NZ554520A (en) | 2010-03-26 |
CA2584211A1 (en) | 2006-05-04 |
EP1805320A2 (en) | 2007-07-11 |
US20060194280A1 (en) | 2006-08-31 |
JP5553963B2 (ja) | 2014-07-23 |
CA2584211C (en) | 2014-07-08 |
MA29027B1 (fr) | 2007-11-01 |
JP2008520190A (ja) | 2008-06-19 |
AU2005299716A1 (en) | 2006-05-04 |
SG156672A1 (en) | 2009-11-26 |
US7928205B2 (en) | 2011-04-19 |
IL182626A0 (en) | 2007-07-24 |
KR20070084483A (ko) | 2007-08-24 |
BRPI0517457A (pt) | 2008-10-07 |
EP1805320A4 (en) | 2009-09-16 |
EP1805320B1 (en) | 2014-09-03 |
JP2013055961A (ja) | 2013-03-28 |
KR101370253B1 (ko) | 2014-03-05 |
RU2007118954A (ru) | 2008-11-27 |
WO2006047340A2 (en) | 2006-05-04 |
EA200700917A1 (ru) | 2007-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20072571L (no) | Fremgangsmater for gjenfolding av rekombinante antistoffer | |
CY1119416T1 (el) | Αντισωματα εναντι των τοξινων toy clostridium difficile (κλωστηριδιο το δυσκολο) και χρησεις εξ' αυτων | |
MX2010002269A (es) | Composiciones y metodos que comprenden proteinas de union para adalimumab. | |
MX2010002683A (es) | Poblaciones de anticuerpos homogeneos. | |
JO3351B1 (ar) | بروتينات رابطة مستضِدة قادرة على ربط مكونات ليمفاوية سدوية سُعترية الشكل | |
MY163480A (en) | Sclerostin binding agents | |
NZ591098A (en) | Engineered anti-il-13 antibodies, compositions, methods and uses | |
NO20091534L (no) | Preparator og fremgangsmater som vedrorer glukagonreseptorantistoff | |
WO2006042158A3 (en) | Methods and compositions for improving recombinant protein production | |
MY169472A (en) | Refolding of recombinant proteins | |
DE602006013428D1 (de) | Chimaere rekombinante antigene von toxoplasma gondii | |
WO2007001264A3 (en) | Method of making recombinant human antibodies for use in biosensor technology | |
NO20062081L (no) | Fremgangsmate | |
DE602005026931D1 (de) | Verwendung von vorstufen von enkephalinen und/oder deren fragmenten in der medizinischen diagnostik | |
DE602005011667D1 (de) | Proteinallergenderivate | |
ATE517340T1 (de) | Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren | |
DK1573058T3 (da) | Fremgangsmåde til forbedring af proteinproduktion | |
BR0215665B1 (pt) | Proteína da endotoxina delta quimérica cry1ea e cry1ca | |
NO20070351L (no) | Materialer og fremgangsmater for forbedring av skalldyrhelse, -immunitet og -vekst | |
ATE516349T1 (de) | Verfahren zur rückfaltung von säuger- glycosyltransferasen | |
EP2042612A3 (en) | A novel nucleotide mixture for improved nucleic acid amplification performance | |
EA200601557A1 (ru) | Уменьшение частоты спонтанных мутаций в клетках | |
MY145649A (en) | Methods for refolding of recombinant antibodies | |
EA200702009A1 (ru) | Усовершенствованный способ экспрессирующего клонирования в клетке-хозяине | |
EP1558735A4 (en) | PROMOTER OF PORK UROPLAKINE II AND METHOD FOR PRODUCING USEFUL PROTEINS USING THE PROMOTER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CREP | Change of representative |
Representative=s name: TANDBERGS PATENTKONTOR AS, POSTBOKS |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |